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Abstract 
Environmental exposure, genetic modification, and aging are considered risky for Parkinson’s 
disease (PD). How these risk factors cooperate to induce progressive neurodegeneration in 
PD remains largely unknown. Paraquat is an herbicide commonly used for weed and grass 
control. Exposure to paraquat is associated with the increased incidence of PD. In contrast to 
familial PD, most sporadic PD cases do not have genetic mutation, but may suffer from partial 
dysfunction of neuron-protective genes as aging. Using conditional transgenic RNAi, we 
showed that temporal silencing of PINK1 expression in adult mice increased striatal dopamine, 
the phenotype that could not be induced by constitutive gene silencing. Moreover, early 
exposure to paraquat sensitized dopaminergic neurons to subsequent silencing of PINK1 gene 
expression, leading to a significant loss of dopaminergic neurons. Our findings suggest a novel 
pathogenesis  of  PD:  exposure  to  environmental  toxicants  early  in  the  life  reduces  the 
threshold of developing PD and partial dysfunction of neuron-protective genes later in the life 
initiates a process of progressive neurodegeneration to cross the reduced threshold of dis-
ease onset. 
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Introduction 
Parkinson disease (PD) results from progressive 
degeneration  of  dopaminergic  neurons  in  the  mid-
brain. PD is characterized by resting tremor, brady-
kinesia, and muscle rigidity (1). At present, no treat-
ment can protect PD-susceptible neurons or prevent 
the  disease  from  progression,  although  dopamine 
replenishment  therapy  temporally  alleviates  PD 
symptoms  (2,  3).  Limited  knowledge  of  PD  patho-
genesis is a major roadblock in the development of 
effective therapy for this devastating disease. Recent 
advance in epidemiological studies suggests PD as a 
multifactorial  disease.  Aging,  genetic  and  environ-
mental factors are considered risky for PD, but how 
these risk factors interact to cause the disease remains 
largely unknown. 
Occupational exposure to pesticides and cumu-
lative exposure to the herbicide paraquat increase the 
risk  of  developing  PD  (4,  5).  Repeated  exposure  to 
environmental  toxicants  is  associated  with  the  in-
creased risk of PD, but no single environmental toxi-
cant  has  been  definitively  linked  to  PD,  suggesting 
that  the  other  risk  factors  must  be  involved  in  the 
development  of  sporadic  PD.  Genetic  factors  influ-
ence the susceptibility to PD. The relatives of PD pa-
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tients show an increased incidence of PD (6). While 
most PD cases are sporadic, about 10% of the cases 
have  pathogenic  mutations  in  the  individual  genes 
including alpha-synuclein, Leucine-Rich Repeat Kinase 2 
(LRRK2),  parkin,  DJ-1,  and  PTEN-induced putative ki-
nase 1 (PINK1) (7-13). Intriguingly, some PD patients 
carry mutation only in the one allele of the recessive 
genes  parkin  and  PINK1  and  some  people  carrying 
mutation in the dominant gene LRRK2 do not develop 
PD in their lives (14-16). The penetrance and expres-
sivity of PD phenotypes appears to be determined not 
only by pathogenic mutation in the identified genes, 
but also by undefined factors. 
Dysfunction  of  neuron-protective  genes  and 
exposure to toxicants may corporate to induce dopa-
minergic neurodegeneration in sporadic PD. Indeed, 
deletion of the neuron-protective genes such as parkin, 
DJ-1, and PINK1 sensitizes dopaminergic neurons to 
the toxicants MPTP and paraquat (17-24). Most spo-
radic PD cases do not have genetic mutation, but they 
may  suffer  from  partial  dysfunction  of  neu-
ron-protective genes later in lives. For example, Par-
kin is S-nitrosylated in PD animal models and in PD 
patients (25, 26). S-nitrosylation inhibits Parkin ligase 
activity  and  induces  accumulation  of  improperly 
folded and biologically inactive protein, causing a loss 
of the neuron-protective functions of Parkin. As ag-
ing, some  neuron-protective genes may  be partially 
inactivated due to epigenetic modification. Exposure 
to  environmental  toxicants  and  genetic  failure  may 
not occur concomitantly, but may occur sequentially. 
Perhaps, exposure to environmental toxicants early in 
the  life  causes  accumulative  effects  and  sensitizes 
dopaminergic  neurons  to  the  partial  dysfunction  of 
neuron-protective genes later in the life, causing spo-
radic PD. To obtain the partial dysfunction of a neu-
ron-protective gene temporally in adult mice, we cre-
ated conditional PINK1-RNAi transgenic mice, which 
were  treated  with  paraquat  before  the  PINK1  gene 
was partially silenced in the adulthood. We observed 
that  early  exposure  to  the  environmental  toxicant 
paraquat sensitized dopaminergic neurons to subse-
quent dysfunction of the PINK1 gene. 
Materials and Methods 
Transgenic mice and behavioral analysis 
PINK1 RNAi transgenic mice have been charac-
terized  (27).  Tamoxifen  inducible  Cre  (CreERT) 
transgenic mice were purchased from Jackson Labor-
atories (28). Cre was driven by the ubiquitous hybrid 
promoter CAG and was expressed in all tissues (28). 
To minimize the leakage of Cre activity, male CreERT 
mice were crossed with female PINK1-RNAi mice to 
produce doubly transgenic offspring. Transgenic mice 
were identified by PCR analysis of tail DNA as de-
scribed previously (27). As stated in the results, par-
aquat (Sigma) was administered to transgenic mice at 
the age of 14 days (0.3 mg/kg, subcutaneous injection; 
once)  or  at  the  age  of  12  weeks  (10mg/kg,  twice  a 
week, for 3 consecutive weeks). To induce a marked 
neurotoxicity, paraquat was repeatedly administered 
to selected mice at the postnatal ages and again in the 
adulthood. At the age of 16 weeks, selected mice were 
injected with 4-hydroxyl Tamoxifen (4-OHT; Sigma) 
to  induce  Cre  activity  and  thus  to  activate  PINK1 
RNAi transgene. To achieve a full activation of PINK1 
RNAi transgene, 4-OHT was administered by intra-
peritoneal  injection  for  5  consecutive  days  (50 
mg/kg/day).  The  locomotor  activity  of  transgenic 
mice within 30 minutes was measured by open field 
activity assay (Med Associates). Animal use followed 
NIH guidelines and the animal use protocol was ap-
proved  by  the  Institutional  Animal  Care  and  Use 
Committees at the University. 
Microdialysis and HPLC analysis 
As  described  previously  (29),  the  extracellular 
level  of  dopamine  released  into  the  striatum  was 
measured by intra-brain microdialysis combined with 
HPLC.  Anesthetized  mice  were  implanted  with  a 
guide cannula the day before dialysis. On the follow-
ing day, dialysis probe (BASi) was inserted through 
the guide cannula into the left striatum (coordinates: 
0.5 mm anterior to bregma; 2 mm left from sagittal 
line; 1.5 mm ventral to the skull). Continuous perfu-
sion was maintained with modified Ringer’s solution 
(147 mm Na+, 4 mm K+, 1.3 mm Ca2+, 1 mm Mg2+, and 
155.6 mm CI-). Dialysates were continuously collected 
and the dialysates of every 20-minute were pooled as 
one  sample  for  HPLC  analysis.  Basal  dopamine  re-
lease  was  established  within  two  hours  when  com-
parable levels of dopamine released were obtained in 
three  consecutive  samplings  (20  minutes  each).  The 
DAT  inhibitor  nomifensine  was  applied  to  dialysis 
solution (200 µM) for 40 minutes (two samplings) and 
enhanced dopamine release was then measured. Do-
pamine  concentration  in  dialysates  was  instantly 
measured by HPLC. The content of striatal dopamine 
was measured by HPLC as described previously (27). 
Briefly, the striatum was dissected from mouse brain 
and was homogenized in 0.1 M perchloric acid. Do-
pamine  in  cleared  lysates  was  measured  by  HPLC. 
Tissue pellets were dissolved in 1M NaOH and pro-
tein  concentration  was  determined.  The  contents  of 
striatal  dopamine  were  adjusted  with  protein  con-




Analysis of gene expression by PCR 
PCR was done as described previously (30). In 
brief, total RNA was isolated from mouse tissues and 
the  total  RNA  of  1µg  was  reversely  transcribed  to 
cDNA with oligo-dT primer (RT kit, Invitrogen). The 
resulting  cDNA  was  used  PCR  amplification.  The 
following  primers  were  used  to  amplify  specific 
mouse  genes:  primers  5’-GCTTGCCAATCCCT 
TCTATG-3’  (forward)  and  5’-CTCTCGCTGGAGC 
AGTGAC-3’  (reverse)  for  PINK1;  primers 
5’-CGGTATAATGGTGGAGTTG-3’  (forward)  and 
5’-ACCCTTAAGTTCAGCGTTACT-3’  (reverse)  for 
L17;  primers  5’-CAGTGTGGACTTCTACCGTC-3’ 
(forward) and 5’-AACTGGAGAAGGCAATCAGC-3’ 
(reverse)  for  DAT;  And  primers  5’- 
CTATCCTCATGGACCACAAC-3’  (forward)  and 
5’-GCTCAGTCACTCTCAGATTC-3’  (reverse)  for 
VMAT2. Cycling conditions were 2 min at 94°C fol-
lowed by 26 or 30 cycles of 15 seconds at 94°C, 30 se-
conds at 60°C, and 20 seconds at 72°C. PCR products 
were resolved on 2% agarose gels. 
Histology and stereological cell counting 
TH  immunostaining  and  stereological  cell 
counting were done as described previously (27, 31). 
Mouse brain was cut on a Cryostat into serial sections 
of 30 µm. Every fourth section through the SNpc was 
immunostained for TH (Pel-Freez; 1: 1000). TH posi-
tive neurons in the SNpc were estimated by stereo-
logical cell counting. 
Statistical analysis 
Statistical significance among group means was 
assessed by ANOVA followed by Tukey’s post hoc 
test. In all analyses, the null hypothesis was rejected at 
the level of 0.05. 
Results 
Exposure to the herbicide paraquat increases the 
risk of PD (5), and thus we chose paraquat as an ex-
ample  of  environmental  toxicants.  Previous  studies 
showed  that  repeated  exposure  to  paraquat  causes 
severe damage to dopaminergic system (32). To assess 
whether  early  exposure  to  environmental  toxicants 
sensitizes dopaminergic neurons to later dysfunction 
of  neuron-protective  genes,  we  first  determined  an 
optimal dosage of paraquat that is sufficient to induce 
a  moderate  loss  of  dopaminergic  neurons  in  the 
mouse strains established  in our lab (Figure 1). We 
treated male C57BL6 mice with paraquat by subcu-
taneous injection and observed a moderate, but sig-
nificant,  loss  of  dopaminergic  neurons  in  the  SNpc 
and a marked depletion of striatal dopamine (Figure 
1). Some mice were injected of paraquat during post-
natal  development  and  again  in  adulthood  and  a 
greater loss of dopaminergic neurons was induced by 
repeated  exposure  to  paraquat  (Figure  1).  Paraquat 
caused  accumulative  damage  to  dopaminergic  neu-
rons  in  mice.  We  further  examined  whether  dopa-
minergic  neurotransmission  would  be  compensated 
in  wildtype  mice  after  the  toxicant  is  removed.  As 
expected, lost dopaminergic neurons were never re-
stored  (Figure  2a).  In  contrast,  synaptic  release  of 
dopamine was significantly increased in the mice after 
paraquat was withdrawn (Figure 2b). Synaptic release 
of  dopamine  is  virtually  related  to  dopaminergic 
function and thus, the findings suggest that the do-
paminergic  function  may  be  compensated  after  the 
risk factor is removed. 
Recessive mutation of the PINK1 gene is linked 
to familial PD (10). We chose PINK1 as an example of 
neuron-protective genes to examine PD pathogenesis. 
We have created conditional transgenic mice that ex-
press PINK1 RNAi upon Cre-mediated activation of 
the transgene and display a significant knockdown of 
PINK1 gene expression by the RNAi (27). Constitutive 
depletion of PINK1 by gene knockout or by transgenic 
RNAi does not induce dopaminergic neuron death in 
the  mutant  mice  (27,  33).  To  avoid  any  potential 
compensation  for  gene  loss  during  mouse  develop-
ment, we used inducible Cre to activate PINK1 RNAi 
transgene  in  adult  mice  and  thus  to  silence  PINK1 
gene expression in the adulthood (Figure 3a). Similar 
to constitutive expression of PINK1 RNAi (27), tem-
poral expression of PINK1 RNAi silenced the expres-
sion of PINK1 and did not affect the expression of the 
dopamine transporter (DAT) and the vesicular monoam-
ine  transporter  2  (VMAT2)  genes  in  transgenic  mice 
(Figure 3a). Consistent with constitutive gene silenc-
ing (27), temporal silencing of PINK1 gene expression 
failed to induce dopaminergic neuron death in trans-
genic mice  at advanced ages (Figure 3c). Unexpect-
edly, temporal silencing of PINK1 gene expression in 
adult mice increased striatal dopamine and enhanced 
locomotor activity (Figure 3b and 3d). The effect of 
PINK1  gene  silencing  on  striatal  dopamine  was  di-
minished as aging (Figure 3). Temporal silencing of 
PINK1 gene expression in adult mice disturbed do-
pamine homeostasis, uncovering the phenotypes that 
were obscured possibly by developmental compensa-
tion. 
To test whether early exposure to environmental 
toxicants sensitizes dopaminergic neurons to partial 
dysfunction of neuron-protective genes, we first ad-
ministered paraquat to PINK1-RNAi transgenic mice 
and then silenced the expression of the PINK1 gene by 
inducing  Cre  activity  (Figure  3a).  Surprisingly,  a 




ergic neurons was induced by a combination of early 
exposure  to  paraquat  and  subsequent  silencing  of 
PINK1  gene  expression,  compared  to  either  of  the 
individual treatments (Figure 4). The results suggest 
that environmental exposure and genetic defects may 
sequentially occur and synergistically induce a pro-




Figure 1. Different combination of paraquat and saline was administered to the mice at the postnatal and 
the adult ages. a, Stereological cell counting revealed a significant loss of TH-positive neurons in the SNpc of paraquat 
(PQ)-treated mice. PQ or saline was administered to male mice at the age of 14 days (0.3mg/kg, once) and further at the age 
of 12 weeks (10mg/kg, twice a week, for 3 consecutive weeks). One week after last PQ injection, the mice were killed for 
analysis. b, HPLC analysis revealed the contents of dopamine in the striatum of PQ-treated and –untreated mice. Data are 
means ± SEM (n = 7-8). * p < 0.05 compared to the control mice only injected of saline; # p < 0.05 compared to the mice 




Figure 2. Elevation of  dopamine  release was observed in mice after  PQ treatment.  a, Stereological cell 
counting  revealed  no  progressive  loss  of  TH-positive  neurons  in  PQ-treated  mice  after  paraquat  withdrawal.  b,  In-
tra-striatum microdialysis revealed extracellular levels of dopamine released from dopaminergic terminals. Male mice were 
injected with PQ at the age of 14 days (0.3mg/kg, once) and further at the age of 12 weeks (10mg/kg, twice a week, for 3 
consecutive weeks). Microdialysis was performed in the mice at 1 or 12 weeks after last injection of PQ. By the end of 
microdialysis, the mice were terminated for stereological cell counting. Data are means ± SEM (n = 5). * p < 0.05. 





Figure 3. Temporal silencing of PINK1 
expression  in  adult  mice  disturbed 
dopaminergic function. a, PCR analysis 
revealed a significant knockdown of PINK1 
expression  by  RNAi.  In  CreERT  and 
PINK1-RNAi double transgenic mice, Cre 
activity  was  induced  by  injection  of 
4-hydroxyl  Tamoxifen  (4-OHT).  Gene 
expression in the midbrain was analyzed by 
PCR one month after 4-OHT induction. b, 
Locomotor  activity  in  30  minutes  was 
measured by open field activity assay. Mice 
at the age of 16 weeks were treated with 
4-OHT to induce gene silencing and were 
tested for locomotor activity at 10 months 
and again at 18 months of age. Data are 
means ± SEM (n = 6). * p < 0.05. c, Stere-
ological cell counting revealed the number 
of TH-positive neurons in the SNpc. Data 
are means ± SEM (n = 5). d, HPLC meas-
ured  the  contents  of  striatal  dopamine. 
Mice of individual group were terminated at 
the age of 10 or 18 months for cell count-











Figure 4. Early exposure to paraquat sensitized dopaminergic neurons to subsequent silencing of PINK1 
gene expression. a, HPLC measured the contents of striatal dopamine in mice. The CreERT single (1, untreated control; 
3, paraquat) and the CreERT/PINK1-RNAi double transgenic mice (group 2 and 4) were injected with paraquat or saline at 
the age of 14 days and further at the age of 12 weeks (10mg/kg, twice a week, for 3 consecutive weeks). One week later, the 
mice were injected with 4-OHT to induce Cre activity and thus to activate PINK1-RNAi. At the age of 20 months, the mice 
were terminated for analysis. b, Stereological cell counting revealed the number of TH-positive neurons in the SNpc. Data 






Exposure  to  environmental  toxicants,  genetic 
modification of critical genes, and physiological aging 
are  suggested  contributing  to  PD  pathogenesis.  We 
showed  that  repeated  exposure  to  paraquat  caused 
accumulative  damage  to  dopaminergic  neurons  in 
mice. By transgenic RNAi, we silenced PINK1 expres-
sion selectively in adult mice and observed a marked 
change  to  dopamine  homeostasis  that  could  not  be 
induced  by  constitutive  silencing  of  PINK1  expres-
sion.  Early  exposure  to  paraquat  sensitized  dopa-
minergic  neurons  to  subsequent  silencing  of  PINK1 
expression in aged mice. Our findings suggest a po-
tential  pathogenesis  for  PD:  exposure  to  environ-
mental toxicants early in the life reduces the threshold 
of  developing  PD;  partial  dysfunction  of  neu-
ron-protective  genes  later  in  the  life  continuously 
compromises dopaminergic function and eventually 
causes the system to cross the reduced threshold of 
developing PD. 
Paraquat  is  an  herbicide  commonly  used  for 
weed and grass control. Exposure to paraquat is as-
sociated with the increased risk of PD (5). In the most 
studies, paraquat is administered by intraperitoneal 
injection and few studies (32) show a statistically sig-
nificant loss of striatal dopamine content, although a 
trend of dopamine loss is always observed. We first 
tested  intraperitoneal  injection  of  paraquat  and  ob-
served a severe loss of treated mice (data not shown). 
Compared to intraperitoneal injection of MPTP, sub-
cutaneous injection of MPTP induces a more severe 
loss of dopaminergic neurons with less variation in 
phenotypic  expression.  We  then  examined  the  sub-
cutaneous injection of paraquat and observed a sig-
nificant loss of striatal dopamine content. Our find-
ings in mice are in great  consistency with previous 
findings in rats that are subcutaneously injected with 
paraquat (34). Intraperitoneal injection may lead to an 
abrupt absorption of neurotoxicant such as paraquat 
and cause a remarkable fluctuation of blood and tis-
sue paraquat, leading to varied phenotypes. By con-
trast,  subcutaneous  injection  of  paraquat  or  MPTP 
may cause less fluctuation of the chemicals in tissues, 
producing a relatively constant effect. Consistent with 
previous findings (32, 35-39), our results confirmed 
that exposure to paraquat caused substantial and ac-
cumulative damage to dopaminergic neurons in mice. 
The  detrimental  effects  of  environmental  toxicants 
may accumulate, but may not cause a progressive loss 
of dopaminergic neurons unless recurrent exposure to 
toxicants happens frequently. In fact, the reduction in 
synaptic release of dopamine was partly compensated 
after paraquat was removed though the lost neurons 
were  never  restored.  The  finding  suggests  that  do-
paminergic dysfunction stopped progression after the 
environmental toxicant was eliminated. Exposure to 
environmental toxicants reduces the threshold of PD 
onset, and continuous presence of risk factors is re-
quired to induce progressive degeneration of dopa-
minergic neurons and to cross the reduced threshold 
of disease onset. Such a lasting insult is likely from an 
endogenous source in sporadic PD. 
As  aging,  the  functions  of  some  neu-
ron-protective  genes  may  be  compromised  (25,  26). 
While pathogenic mutation of the two PINK1 alleles 
definitely causes PD (10), mutation of the one PINK1 
allele  also  increases  PD  susceptibility  (40,  41),  sug-
gesting  that  PINK1  has  dose-dependent  effects  on 
dopaminergic neurons. Unlike familial PD, sporadic 
PD  may  not  have  inheritable  mutation  in  neu-
ron-protective  genes,  but  may  suffer  from  partial 
dysfunction of the beneficial genes later in the life (25, 
26). In contrast to previous studies (42-44), our study 
applied  transgenic  RNAi  technology  to  partially  si-
lence  the  expression  of  the  neuron-protective  gene 
PINK1 selectively in adult mice. Compared to consti-
tutive  gene  knockout,  temporal  silencing  of  PINK1 
expression in adult mice increased the content of stri-
atal dopamine, possibly because it avoided develop-
mental compensation for the gene loss. Interestingly, 
simultaneous deletion of parkin, DJ-1, and PINK1 also 
increases  striatal  dopamine  in  the  triple  knockout 
mice at advanced ages (45). By contrast, deleting any 
of the three genes (parkin, DJ-1, and PINK1) alone fails 
to induce the phenotype in the lifetime of single-gene 
knockout  mice  (33,  46-48).  Intriguingly,  striatal  do-
pamine  was  decreased  to  the  control  level  in  our 
PINK1-RNAi  mice  at  advanced  ages.  Alteration  to 
dopamine neurotransmission may be an early event 
in the process of dopaminergic neurodegeneration. 
Given that environmental toxicants cause accu-
mulative damage to dopaminergic neurons, exposure 
to  toxicants  any  time  in  the  life  will  reduce  the 
threshold of developing PD and will increase the in-
cidence of PD. Immature brain is vulnerable to neu-
rotoxins  (32),  and  exposure  to  environmental  toxi-
cants early in the life may play an important role in 
PD pathogenesis. Previous studies have shown that 
complete  and  constitutive  deletion  of  neu-
ron-protective genes such as parkin, DJ-1, and PINK1 
sensitizes  dopaminergic  neurons  to  neurotoxins 
(17-24).  Previous  studies  all  test  the  effects  of  envi-
ronmental toxicants on dopaminergic system after a 
neuroprotective  gene  is  permanently  inactivated  in 
mice. By striking contrast, we used a reverse order of 
gene-environment  interaction  to  examine  how  PD 




sessed the effects of early paraquat treatment on the 
phenotypic expression caused by partial and temporal 
depletion of the PINK1 gene, testing a new theory on 
PD pathogenesis. Conditional transgenic RNAi pro-
vides  an  unprecedented  tool  for  temporal,  partial 
gene depletion in animal models. Temporal silencing 
of PINK1 expression by transgenic RNAi induced a 
significant  loss  of  dopaminergic  neurons  in  aged 
mice, which received paraquat treatment early in their 
lives. Endogenous and exogenous toxins may execute 
toxicity to dopaminergic neurons via varying mecha-
nisms (49-53). Since RNAi may cause nonspecific tox-
icity or side-effects, it could not be ruled out whether 
the  outcome  in  PINK1-RNAi  transgenic  mice  is  a 
combined  effect  of  environmental  toxicant,  gene  si-
lencing,  and  RNAi  toxicity.  Regardless  of  mecha-
nisms, sequential insults from multiple hits may cause 
accumulative damage to dopaminergic neurons and 
any lasting insults may initiate a progressive degen-
eration of dopaminergic neurons, inducing PD onset. 
The novelty of this hypothetic PD pathogenesis war-
rants further clinical and epidemiological studies. 
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